Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC).

9094Background: Nazartinib (EGF816) is a third-generation EGFR-TKI selective for activating and T790M mutations while sparing wild-type EGFR. In the Phase I part of a Phase I/II multicenter study o...